drugset / Trial / NCT02758587
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
Phase 1/2
Unknown
59 enrolled
NHS Greater Glasgow and Clyde
Cancer Research UK · collabMerck Sharp & Dohme LLC · collabQueen's University, Belfast · collabUniversity of Edinburgh · collabUniversity of Glasgow · collabUniversity of Leicester · collabUniversity of Southampton · collabVerastem, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will explore whether defactinib (a FAK inhibitor) can be safely and tolerably combined with pembrolizumab (a PD-1 inhibitor) and will look for early indications of improved anticancer immunotherapy. It will focus on three key cancers, all in clear need of improved therapies - NSCLC, pancreatic cancer and mesothelioma.
Timeline
- Start
- 2017-07-04
- Primary completion
- 2019-05
- Completion
- 2021-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Defactinib | Small molecule | 200 mg | Oral |
| Subject | Defactinib | Small molecule | 400 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |